Cardlytics, Inc. (NASDAQ:CDLX) Receives $13.00 Consensus PT from Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $12.67.

CDLX has been the subject of a number of research analyst reports. Craig Hallum lowered their target price on Cardlytics from $18.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Northland Capmk upgraded Cardlytics to a “strong-buy” rating in a report on Tuesday, June 18th. Lake Street Capital lifted their target price on Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Northland Securities initiated coverage on Cardlytics in a report on Tuesday, June 18th. They set an “outperform” rating and a $14.00 price objective for the company. Finally, Bank of America restated a “neutral” rating and set a $11.00 price objective on shares of Cardlytics in a report on Thursday.

Insider Activity at Cardlytics

In related news, CEO Karim Saad Temsamani sold 43,129 shares of Cardlytics stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $8.65, for a total transaction of $373,065.85. Following the transaction, the chief executive officer now owns 385,530 shares of the company’s stock, valued at $3,334,834.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, COO Amit Gupta sold 23,416 shares of Cardlytics stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $11.91, for a total transaction of $278,884.56. Following the transaction, the chief operating officer now owns 122,676 shares of the company’s stock, valued at $1,461,071.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Karim Saad Temsamani sold 43,129 shares of Cardlytics stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total value of $373,065.85. Following the transaction, the chief executive officer now directly owns 385,530 shares in the company, valued at approximately $3,334,834.50. The disclosure for this sale can be found here. Insiders have sold a total of 79,435 shares of company stock valued at $828,269 over the last 90 days. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Kent Lake Capital LLC purchased a new position in Cardlytics in the first quarter worth $3,622,000. Blackstone Inc. purchased a new position in Cardlytics in the first quarter worth $2,029,000. Perbak Capital Partners LLP purchased a new position in Cardlytics in the first quarter worth $2,348,000. Price T Rowe Associates Inc. MD boosted its position in Cardlytics by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Cardlytics in the first quarter worth $1,906,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Price Performance

Shares of CDLX opened at $8.04 on Wednesday. Cardlytics has a 1 year low of $5.53 and a 1 year high of $20.52. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.13 and a quick ratio of 2.13. The company has a market capitalization of $392.19 million, a price-to-earnings ratio of -1.82 and a beta of 1.67. The business has a 50-day moving average of $10.41 and a 200-day moving average of $9.57.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share for the quarter. The business had revenue of $67.61 million during the quarter. Cardlytics had a negative return on equity of 25.36% and a negative net margin of 55.23%.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.